calcipotriene
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- calcipotriene
- Generic name
- CALCIPOTRIENE
- Manufacturer
- Glenmark Pharmaceuticals Inc.,USA
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 7ec750f6-26ea-46bc-aa7b-174fd25253a2
- SPL ID
- 2feacaaa-677d-4ab6-878e-4e909f57488d
- Version
- 8
- Effective date
- 2026-10-07
- Source export date
- 2026-11-13
- Source partition
- 14
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0014-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/087e7a9c7af51c6b12a0e8fd611a27cb8635e1910ad160b89995da9a4b39b1b3/drug-label-0014-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 18:17:57
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 205772 | derived:openfda.application_number |
| application number | ANDA205772 | openfda.application_number | |
| brand name | calcipotriene | openfda.brand_name | |
| generic name | CALCIPOTRIENE | openfda.generic_name | |
| manufacturer name | Glenmark Pharmaceuticals Inc.,USA | openfda.manufacturer_name | |
| ndc | package | 68462-501-65 | openfda.package_ndc |
| ndc | package | 68462-501-66 | openfda.package_ndc |
| ndc | product | 68462-501 | openfda.product_ndc |
| ndc11 | package | 68462050165 | derived:openfda.package_ndc |
| ndc11 | package | 68462050166 | derived:openfda.package_ndc |
| rxcui | 313921 | openfda.rxcui | |
| spl id | 2feacaaa-677d-4ab6-878e-4e909f57488d | id | |
| spl set id | 7ec750f6-26ea-46bc-aa7b-174fd25253a2 | set_id | |
| unii | 143NQ3779B | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Contact dermatitis, including allergic contact dermatitis, has been observed with the use of calcipotriene cream.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Clinical Trials Experience In controlled clinical trials, the most frequent adverse experiences reported for calcipotriene cream, 0.005% were cases of skin irritation, which occurred in approximately 10 to 15% of patients. Rash, pruritus, dermatitis and worsening of psoriasis were reported in 1 to 10% of patients. Postmarketing Experience The following adverse reactions have been identified during postapproval use of calcipotriene Cream. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Metabolism and nutrition disorders: hypercalcemia Renal and urinary disorders: hypercalciuria Skin and subcutaneous tissue disorder: application site edema, application site pain, contact dermatitis (including allergic contact dermatitis), depigmentation, dry skin, erythema, hyperpigmentation, hypopigmentation, photosensitivity, rash (including erythematous, maculo-papular, and pustular), skin burning sensation, skin exfoliation, and urticaria. To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.